Shaping a sound supply chain ecosystem
21 April 2016
12:30 to 14:00
This event has now passed. To browse our upcoming events click here.
Please join us to find out more about
the complexities of the pharmaceutical supply chain,
to hear what experts think are the essential elements for robust
health policies for a sustainable supply chain environment,
and to discover innovative solutions.
To get registered, please have a look under our Programme section. Thank you.
Open session between speakers and public on the following:
Holistic overview of the opportunities & challenges facing the supply chain,
In-depth insight of supply chains in fragile environments,
Real-life experiences from manufacturers, wholesalers and healthcare providers, and
Creative and alternative solutions for the future.
Please register your attendance at http://ghf2016.g2hp.net/register/ to the Geneva Health Forum 2016.
If you plan to attend for the day only (21 April), please insert the following Promotional Code “GHF16IFPMA” onto the registration form.
Representatives from Permanent Missions to the UNOG interested in attending should contact Ms. Noria Mezlef, Coordinator (firstname.lastname@example.org) directly.
For WHO & UNAIDS Staff, please send an email to Ms. Christine Maheut (email@example.com) for registration.
For any other registration-related inquiries, please email firstname.lastname@example.org.
Sukaina has been reporting on all aspects of the pharmaceutical and biotechnology space since 2000. In her role as News Editor on Scrip Intelligence, she is tasked with ensuring the publication continues to provide the business critical information that its readers rely on. Previously, Sukaina was the editor of BioVenture View and BioPeople. Sukaina is often asked to appear on TV and radio in the UK to commentate on commercial and R&D strategy related to the pharmaceutical industry. She has a PhD in biochemistry and molecular biology from University College London and a BSc (Hons) in Applied Biochemistry from Brunel University, UK.
Mr. Kalland is responsible for the relationship with Pharmaceutical and Healthcare Manufacturers. Development and selling of services for Manufacturers.
Responsible for two Synergy workstreams for Walgreens Boots Alliance Development GmbH (Branded Pharma & Branded non Pharma)
Cheryl S. Watson has over 20 years of experience in pharmaceutical industry, supporting the development and manufacture of small molecule products, biotechnology products, and vaccines. Cheryl began her pharmaceutical career working in manufacturing development for vaccines and later transitioned into a supervisory role in Quality Control laboratories. For the past 16 years, Cheryl has been working in regulatory affairs supporting the global registration of medicinal products, including life cycle support associated with manufacturing changes for authorized products. Currently, she is an Associate Director at Bristol-Myers Squibb Company in Global Regulatory Science and Biometrics, where she is supporting registrational activities for biotherapeutic medicines.
Christophe Hambÿe is Belgian and was born in 1966. He is married and has
three children. He lives in Geneva region.
Holder of a Law Degree from Université Catholique de Louvain and a Special
Degree in Corporate Law and Finance from the Vrije Universiteit van Brussel, he has extensive
international humanitarian management experience with the ICRC and with MSF, especially in the
fields of Supply Chain and Operational Management, Finance and Administration and Fundraising.
In his career, Christophe worked in the following assignments:
– 05/2014-Present: ICRC, Head of Logistics Division, Geneva
– 08/2011-05/2014: ICRC, Head of Donors Relation Unit, Geneva
– 01/2005-08/2011: ICRC, Deputy Head of Logistics Division (Operations), Geneva
– 09/1999-12/2004: ICRC, Logistics Coordinator and Head of Regional Logistics Centre, Dili,
Nairobi, Peshawar, Khartoum and Belgrade
– 11/1996-06/1999: MSF/B, Head of Mission, Ethiopia
– 10/1993-10/1996: MSF Supply/Transfer, Head of Supply Operations, Brussels
– 08/1992-08/1993: MSF/B, Administration and Logistics Coordinator, Moscow and the CIS
– 08/1991-08/1992: Belgian Armed Forces, Infantry Platoon Commander
– 04/1990-05/1991: Martin International Ltd., Financial Controller, Hong-Kong
He speaks fluent French and English, good Dutch and has notions of German, Russian and Serbo-
Hitesh Hurkchand has over 16 years of experience in international development with a focus on Global Health programs. His health systems experience includes global procurement and supply chain, medicines supply, health financing, governance, strategic information (SI), health policy development, program monitoring & evaluation (M&E), general management and capacity building. He has managed large scale bilateral health programs in Southern and East Africa and currently coordinates and convenes Global Interagency Coalitions. In Africa, he has worked and negotiated with National Government to effect policy level analysis and change in the health sector, with lasting effects, notably in South Africa, Kenya, Lesotho, Swaziland and Zambia. At WHO, Hitesh supports the Department of Essential Medicines and Health Products, (Policy, Access and Use) for the development of strategies to reduce the incidence of Global Medicines Shortage. Other areas of his focus include emergency response and integration of pediatric medicines in country supply chains and WHO’s Engagement with the Global Inter Agency Supply Chain Group (ISG) and Inter Agency Pharmaceutical Coordination Group (IPC). Hitesh convenes and facilitate interagency technical and policy level discussions with the ISG, that include the World Bank Group, WHO, PAHO, UNFPA, UNICEF, the Bill and Melinda Gates Foundation, GAVI Alliance, USAID, The Global Fund to fight AIDS, TB and Malaria, DFID, NORAD, The German Development Bank, The World Food Program, the Global Drug Facility and Global Affairs Canada. At the ISG, Hitesh works with development agencies to maintain communications and encourage alignment across different agency supply chain investments to bring greater impact to individual agency strategies as well as those that are common at a global and country level.